Treatment of cancer with 2-deoxyglucose

• US 6,979,675 B2
• Filed: 01/09/2004
• Issued: 12/27/2005
• Est. Priority Date: 01/10/2003
• Status: Expired due to Fees

• Current Assignee: Threshold Pharmaceuticals, Inc. (Molecular Templates, Inc.)
• Original Assignee: Threshold Pharmaceuticals, Inc. (Molecular Templates, Inc.)
• Inventors: Tidmarsh, George
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): McIntosh, III, Traviss C.
• Application Number:
  US10/754,239
• Publication Number:
  US 20040167079A1
• Time in Patent Office: 718 Days
• Field of Search: 514/23, 514/24, 514/25
• US Class Current: 514/23
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.

Claims

1. A method of treating cancer in a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily to said patient in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.

2. The method of claim 1 wherein said 2-DG is administered daily for at least two weeks.

3. The method of claim 1, wherein said 2-DG is administered daily for at least one week.

4. The method of claim 1, wherein said 2-DG is administered daily for at least ten consecutive days.

5. The method of claim 1, wherein said daily dose is in the range of about 1 mg of 2-DG per kg of patient weight to about 1 g/kg.

6. The method of claim 1, wherein said daily dose is in the range of about 25 mg/kg to about 50 mg/kg.

17. The method of claim 1, wherein said patient has a solid tumor cancer.

7. A method of treating a human cancer patient, which method comprises administering to said patient a therapeutically effective dose of 2-DG in combination with another anti-cancer agent, wherein the therapeutically effective dose of 2-DG is obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.

8. The method of claim 7, wherein said cancer is a multi-drug resistant cancer.

9. The method of claim 8, wherein said anti-cancer agent is an agent to which said cancer is resistant in the absence of 2-DG.

10. The method of claim 7, wherein said anti-cancer agent is administered to the mammal at a dose that is lower than the recommended effective dose for administration when not administered in combination with 2-DG.

11. The method of claim 7, wherein said cancer is a cancer selected from the group consisting of non-small-cell lung cancer, head and neck cancer, colorectal cancer, and breast cancer.

12. The method of claim 7, wherein said therapeutically effective dose of 2-DG is obtained by administering 2-DG daily for at least a week.

13. The method of claim 7, wherein said anti-cancer agent is selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.

14. A method of treating cancer in a human patient having a solid tumor, which method comprises administering to said patient a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days.

15. A method of treating cancer in a human cancer patient, which method comprises co-administering to said patient (i) a therapeutically effective dose of 2-deoxy-D-glucose (2-DG), said therapeutically effective dose obtained by orally administering 2-DG daily in a range of about 25 mg of 2-DG per kg of patient weight to about 150 mg of 2-DG per kg of patient weight for at least five consecutive days, and (ii) an anti-cancer agent selected from the group consisting of docetaxel, paclitaxel, cisplatin, and carboplatin.

16. The method of claim 15, wherein said patient has a solid tumor cancer.